Form 8-K - Current report:
SEC Accession No. 0001104659-25-070245
Filing Date
2025-07-24
Accepted
2025-07-24 08:40:38
Documents
13
Period of Report
2025-07-24
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2521489d1_8k.htm   iXBRL 8-K 31359
2 EXHIBIT 3.1 tm2521489d1_ex3-1.htm EX-3.1 11033
  Complete submission text file 0001104659-25-070245.txt   212247

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20250724.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20250724_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20250724_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2521489d1_8k_htm.xml XML 3674
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 251144641
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)